Is Wegovy the same as Mounjaro?

No. Wegovy is semaglutide; Mounjaro is tirzepatide. Different molecules and label focuses.

Which causes more weight loss, Wegovy or Mounjaro?

Head-to-head obesity data in SURMOUNT-5 used Zepbound (tirzepatide) vs Wegovy (semaglutide): 20.2% vs 13.7% average loss at 72 weeks. Mounjaro is the diabetes tirzepatide brand.

Is Mounjaro approved for weight loss?

In the US, Zepbound is the tirzepatide brand with a chronic weight-management label. Mounjaro's primary label is type 2 diabetes.

Wegovy vs Mounjaro: Semaglutide vs Tirzepatide

Wegovy vs Mounjaro: semaglutide vs tirzepatide — approved uses, SURMOUNT-5 and SURPASS themes, side effects and user reports. Not medical advice.

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

Short answer

Wegovy is a semaglutide brand with a chronic weight-management label (GLP-1 only). Mounjaro is a tirzepatide brand labelled for type 2 diabetes (GLP-1 and GIP). The weight-management tirzepatide brand is Zepbound; the diabetes semaglutide brand is Ozempic. So "Wegovy vs Mounjaro" compares a weight-labelled semaglutide product with a diabetes-labelled tirzepatide product — related molecules, different label focus. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

Side by side

	Wegovy	Mounjaro
Active ingredient	Semaglutide	Tirzepatide
Receptor targets	GLP-1	GLP-1 and GIP
Main US label focus	Chronic weight management (+ CV risk reduction in eligible adults)	Type 2 diabetes
Sister brand	Ozempic (diabetes)	Zepbound (weight)
Molecule page	Semaglutide vs tirzepatide	Semaglutide vs tirzepatide

Head-to-head trial themes

SURMOUNT-5 compared weight-management strengths of tirzepatide (Zepbound) with semaglutide (Wegovy) in adults with obesity without diabetes: average weight loss 20.2% vs 13.7% at 72 weeks. SURPASS-2 compared tirzepatide with Ozempic-strength semaglutide in type 2 diabetes and found greater HbA1c and weight reductions with tirzepatide. Those trials inform the molecule comparison; they are not a licence to choose brands without a clinician. Last reviewed October 15, 2026.

Side effects

Both classes commonly cause gastrointestinal effects — nausea, vomiting, diarrhoea, constipation and abdominal pain — especially early on. Labels carry a boxed warning about thyroid C-cell tumours seen in rodents and warn about pancreatitis, gallbladder disease and other risks. Story counts: semaglutide and tirzepatide reports; brand pages Wegovy side effects and Mounjaro side effects.

What users report here

Switchers often compare the molecules: #384 preferred tirzepatide's appetite effect after semaglutide; #194 describes forgetting lunch after switching. Browse hubs rather than treating any confession as a rate.

More confessions from the archive

Community Q&A

Is Wegovy the same as Mounjaro?: No. Wegovy is semaglutide; Mounjaro is tirzepatide. Different molecules and label focuses.
Which causes more weight loss, Wegovy or Mounjaro?: Head-to-head obesity data in SURMOUNT-5 used Zepbound (tirzepatide) vs Wegovy (semaglutide): 20.2% vs 13.7% average loss at 72 weeks. Mounjaro is the diabetes tirzepatide brand.
Is Mounjaro approved for weight loss?: In the US, Zepbound is the tirzepatide brand with a chronic weight-management label. Mounjaro's primary label is type 2 diabetes.
Does this page give dosing advice?: Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

Sources

Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.